TRC120038, a Novel Dual AT₁/ET_A Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats

Figure 4

(a) Percent change from basal levels in urinary protein excretion profile of male ob-ZSF1 rats treated with vehicle, TRC120038, or candesartan. ^∗𝐏≤𝟎.𝟎𝟓 versus vehicle; ^∗∗𝐏≤𝟎.𝟎𝟓 TRC120038 versus candesartan by one-way ANOVA with multiple comparison using Tukey post hoc test. (b) Urinary albumin to creatinine ratio profile of male ob-ZSF1 rats treated with vehicle, TRC120038, or candesartan. ^∗𝐏≤𝟎.𝟎𝟓 versus vehicle; ^∗∗𝐏≤𝟎.𝟎𝟓 TRC120038 versus candesartan by one-way ANOVA with multiple comparison using Tukey post hoc test.

(a)

(b)